Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
FreeGuest Editorial Cancer centers, health providers should clearly signal that they welcome LGBTQI+ patients June 14, 2024Vol.50 No.24By NFN Scout
FreeIn the Archives In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs June 14, 2024Vol.50 No.24
EditorialFree The Cancer Letter receives six journalism, design awards June 14, 2024Vol.50 No.24By Katie Goldberg
Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows June 07, 2024Vol.50 No.23By Matthew Bin Han Ong
Conversation with The Cancer Letter Fred Hutch’s Christopher Li: Cancer centers should commit more resources to meet NCI’s Plan to Enhance Diversity requirements June 07, 2024Vol.50 No.23By Matthew Bin Han Ong
Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC June 07, 2024Vol.50 No.23By Jacquelyn Cobb and McKenzie Prillaman
Trials & Tribulations Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists June 07, 2024Vol.50 No.23By Rebecca Sutphen
Conversation with The Cancer LetterFree ACS, ASCO combine online patient information services June 01, 2024Vol.50 No.23By Paul Goldberg
